Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Invectys

Pierre Langlade-Demoyen

Sylvain Cardinaud

Fransisco Garcia Pons

Christine Neuveut

Olivier Adotevi

François Lemonnier

André Habel

Hüseyin Firat

Marie-Louise Michel

Andreas Suhrbier

Julien Caumartin

Jeanne Menez-Jamet

Kostas Kosmatopoulos

Stéphanie Graff-Dubois

Maria De Las Nieves Loustau

Francisco Garcia Pons

This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.

Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

An antibody or antigen-binding fragment thereof which specifically binds the &#x3b1;3 domain of a HLA-G protein, in particular binds the &#x3b2;2-microglobulin free HLA-G protein exhibiting an &#x3b1;3 domain. The nucleic acid molecules encoding a human HLA-G &#x3b1;3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to HLA-G proteins, and/or improving or treating conditions showing HLA-G+ lesions, and/or improving or treating a neoplasic condition or disease. A method of producing the antibody or antigen-binding fragment thereof, immunogenic compositions for use to elicit in a host an immune response against the &#x3b1;3 domain of HLA-G protein, and an in vitro method for detecting HLA-G protein in a sample are also described.

Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof

This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.

The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.

Identification of new CD8 epitopes from HIV-1 proteins

H-2 class I negative, HLA-A2.1 transgeniic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.

Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences

CD8 epitope from HIV-1 protein Vpu

Growing community of inventors

Paris, France

Pierre Langlade-Demoyen